CAPR Stock Drop Alert: Capricor Therapeutics Stock Plummets Over 64% After FDA Briefing Documents Raise Concerns, Triggering Securities Fraud Investigation by BFA Law businesswire.com July 30, 2026 at 11:09 AM ET CAPR The stock plummeted over 64% following FDA briefing documents that raised concerns, leading to a securities fraud investigation. This indicates significant negative developments.